Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catheter Precision (VTAK) Shares Outstanding (Weighted Average) (2017 - 2025)

Catheter Precision (VTAK) has disclosed Shares Outstanding (Weighted Average) for 9 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 529.09% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 529.09% year-over-year, with the annual reading at $1.1 million for FY2025, 529.09% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $1.1 million at Catheter Precision, down from $1.3 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $668.5 million in Q3 2022, with the low at $90.0 in Q3 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $82.0 million, with a median of $1.1 million recorded in 2022.
  • The sharpest move saw Shares Outstanding (Weighted Average) crashed 100.0% in 2021, then soared 742771011.11% in 2022.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $101000.0 in 2021, then soared by 923.59% to $1.0 million in 2022, then rose by 6.81% to $1.1 million in 2023, then crashed by 84.44% to $171774.0 in 2024, then skyrocketed by 529.09% to $1.1 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $1.1 million, $1.3 million, and $13.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.